Delivery types include injectable, oral (non-liposomal), liposomal, and topical
Patients should maintain a rotation schedule and visually inspect previous application sites for persistent redness, itching, or skin changes that might indicate an adverse reaction
Injection-site reactions Community reports cluster around mild redness or itching at the subcutaneous injection site, typically lasting under 24 hours
In another Clinical Trial, Thomas et al
Current epidemiological data rank it as the seventh leading cause of cancer-related mortality worldwide, with projections indicating it may become the second leading cause in the United States by 2030 [2, 3]
Intravenous or intramuscular delivery bypasses the intestinal lumen, preventing any interaction with microbial enzymes responsible for TMA formation